Large Clinical Trial Will Test Combination Monoclonal Antibody Therapy for Mild to Moderate COVID-19

Large Clinical Trial Will Test Combination Monoclonal Antibody Therapy for Mild to Moderate COVID-19

A Phase 2/3 clinical trial has begun to evaluate a combination investigational monoclonal antibody therapy for its safety and efficacy in people who have mild or moderate COVID-19. The two experimental antibodies, BRII-196 and BRII-198, target SARS-CoV-2, the virus that causes COVID-19. With the initiation of the BRII-196 and BRII-198 experimental monoclonal antibodies in the ACTIV-2 study, the LY-COV555 sub-study will close to enrollment. Data on each antibody from Phase I trials that are currently ongoing support the doses being used in the ACTIV-2 trial. The trial will initially enroll 220 participants with mild or moderate COVID-19, who are at risk for disease progression.

About Us

At Wellness Axis we want to encourage habits of wellness, Increase awareness of factors and resources contributing to well-being, Inspire and empower individuals to take responsibility for their own health, and to support a sense of community. Wellness can be thought of as the quality or state of being in good health.

Subscribe to our newsletter!